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Abstract
Background: Drug-target networks are receiving a lot of attention in late years, given its relevance for
pharmaceutical innovation and drug lead discovery. Different in silico approaches have been proposed for the
identification of new drug-target interactions, many of which are based on kernel methods. Despite technical
advances in the latest years, these methods are not able to cope with large drug-target interaction spaces and to
integrate multiple sources of biological information.
Results: We propose KronRLS-MKL, which models the drug-target interaction problem as a link prediction task on
bipartite networks. This method allows the integration of multiple heterogeneous information sources for the
identification of new interactions, and can also work with networks of arbitrary size. Moreover, it automatically selects
the more relevant kernels by returning weights indicating their importance in the drug-target prediction at hand.
Empirical analysis on four data sets using twenty distinct kernels indicates that our method has higher or comparable
predictive performance than 18 competing methods in all prediction tasks. Moreover, the predicted weights reflect
the predictive quality of each kernel on exhaustive pairwise experiments, which indicates the success of the method
to automatically reveal relevant biological sources.
Conclusions: Our analysis show that the proposed data integration strategy is able to improve the quality of the
predicted interactions, and can speed up the identification of new drug-target interactions as well as identify relevant
information for the task.
Availability: The source code and data sets are available at www.cin.ufpe.br/~acan/kronrlsmkl/.
Keywords: Artificial intelligence, Supervised machine learning, Kernel methods, Multiple kernel learning,
Drug discovery
Background
Drug-target networks are receiving a lot of attention in
late years, given their relevance for pharmaceutical inno-
vation and drug repositioning purposes [1–3]. Although
the amount of known interactions between drugs and
target proteins has been increasing, the number of tar-
gets for approved drugs is still only a small proportion
(< 10 %) from the human proteome [1]. Recent advances
on high-throughput methods provide ways for the pro-
duction of large data sets about molecular entities as
drugs and proteins. There is also an increase in the avail-
ability of reliable databases integrating information about
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interactions between these entities. Nevertheless, as the
experimental verification of such interactions does not
scale with the demand for innovation, the use of computa-
tional methods for the large scale prediction is mandatory.
There is also a clear need for systems-based approaches to
integrate these data for drug discovery and repositioning
applications [1].
Recently, an increasing number of methods have been
proposed for drug-target interaction (DTI) prediction.
They can be categorized in ligand-based, docking-based,
or network-based methods [4]. The docking approach,
which can provide accurate estimates to DTIs, is com-
putationally demanding and requires a 3D model of the
target protein. Ligand-based methods, such as the quan-
titative structure activity relationship (QSAR), are based
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on a comparison of a candidate ligand to the known lig-
ands of a biological target [5]. However, the utility of these
ligand-based methods is limited when there are few lig-
ands for a given target [2, 4, 6]. Alternatively, network
based approaches use computational methods and known
DTIs to predict new interactions [4, 5]. Even though
ligand-based and docking-based methods are more pre-
cise when compared to network based approaches, the
latter are more adequate for the estimation of new inter-
actions from complete proteomes and drugs catalogs [1].
Therefore, it can indicate novel candidates to be evaluated
by more accurate methods.
Most network approaches are based on bipartite graphs,
in which the nodes are composed of drugs (small
molecules) and biological targets (proteins) [3, 7, 8]. Edges
between drugs and targets indicate a known DTI (Fig.1).
Given a known interaction network, kernel based meth-
ods can be used to predict unknown drug-target inter-
actions [2, 9–11]. A kernel can be seen as a similarity
matrix estimated on all pairs of instances. The main
assumption behind network kernel methods is that simi-
lar ligands tend to bind to similar targets and vice versa.
These approaches use base kernels to measure the sim-
ilarity between drugs (or targets) using distinct sources
of information (e.g., structural, pharmacophore, sequence
and function similarity). A pairwise kernel function, which
measures the similarity between drug-target pairs, is
obtained by combining a drug and a protein base kernel
via kernel product.
The majority of previous network approaches use clas-
sification methods, as Support Vector Machines (SVM),
to perform predictions over the drug-target interaction
space [2, 4]. However, such techniques have major limi-
tations. First, they can only incorporate one pair of base
kernels at a time (one for drugs and one for proteins)
to perform predictions. Second, the computation of the
pairwise kernel matrix for the whole interaction space (all
possible drug-target pairs) is computationally unfeasible
even for a moderate number of drugs and targets. More-
over, most drug target interaction databases provide no
true negative interaction examples. The common solution
for these issues is to randomly sample a small proportion
of unknown interactions to be used as negative examples.































Fig. 1 Overview of the proposed method. a The drug-target is a bipartite graph with drugs (left) and proteins (right). Edges between drugs and
proteins (solid line) indicates a known drug-protein interaction. The drug-protein interaction problem is defined as finding unknown edges (dashed
lines) with the assumption that similar drugs (or proteins) should share the same edges. b KronRLS-MKL uses several drugs (and protein) kernels to
solve the drug-target interaction problem. Distinct Kernels are obtained by measuring similarities of drugs (or proteins) using distinct information
sources. c KronRLS-MKL provides not only novel predicted interactions as it indicates the relevance (weights) of each kernel used in the predictions
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small drug-target pairwise kernel, it generates an easier
but unreal classification task with balanced class size [12].
An emerging machine learning (ML) discipline focused
on the search for an optimal combination of kernels,
called Multiple Kernel Learning (MKL) [13]. MKL-like
methods have been previously proposed to the prob-
lem of DTI prediction [14–16] and the closely related
protein-protein interaction (PPI) prediction problem [17,
18]. This is extremely relevant, as it allows the use of
distinct sources of biological information to define sim-
ilarities between molecular entities. However, since tra-
ditional MKL methods are SVM-based [13, 19], they are
subject to memory limitations imposed by the pairwise
kernel, and are not able to perform predictions in the com-
plete drugs vs. protein space. Moreover, MKL approaches
used in PPI prediction problem [17, 18] and protein
function prediction [20, 21] can not be applied to bipar-
tite graphs, as the problem at hand. Currently, we are
only aware of two recent works [19, 22] proposing MKL
approach to integrate similarity measures for drugs and
targets.
Drug-target prediction fits a link prediction problem
[4], which can be solved by a Kronecker regularized least
squares approach (KronRLS) [10]. A single kernel version
of this method has been recently applied to drug-target
prediction problem [10, 11]. A recent survey indicated
that KronRLS outperforms SVM based methods in DTI
prediction [2]. KronRLS uses Kronecker product algebraic
properties to be able to perform predictions on the whole
drug-target space, without the explicit calculation of the
pairwise kernels. Therefore, it can cope with problems on
large drugs vs. proteins spaces. However, KronRLS can
not be used on a MKL context.
In this work, we propose a new MKL algorithm to
automatically select and combine kernels on a bipar-
tite drug-protein prediction problem, the KronRLS-MKL
algorithm (Fig 1). For this, we extend the KronRLSmethod
to a MKL scenario. Our method uses L2 regularization
to produce a non-sparse combination of base kernels.
The proposed method can cope with large drug vs. target
interaction matrices; does not requires sub-sampling of
the drug-target network; and is also able to combine and
select relevant kernels. We perform an empirical analysis
using drug-target datasets previously described [23] and a
diverse set of drug kernels (10) and protein kernels (10).
In our experiments, we considered three different sce-
narios in the DTI prediction [2, 11, 24]: pair prediction,
where every drug and target in the training set have
at least one known interaction; or the ‘new drug’ and
‘new target’ setting, where some drugs and targets are
present only in the test set, respectively. A comparative
analysis with top performance single kernel approaches
[2, 8, 10, 25–27] and all competing integrative approaches
[14, 15, 22] demonstrates that our method is better or
competitive in the majority of evaluated scenarios. More-
over, KronRLS-MKL was able to select and also indicate
the relevance of kernels, in the form of weights, for each
problem.
Methods
In this work, we propose an extension of the Kron-
RLS algorithm under recent developments of the MKL
framework [28] to address the problem of link predic-
tion on bipartite networks with multiple kernels. Before
introducing our method, we will describe the RLS and
the KronRLS algorithms (for further information, see
[10, 11]).
RLS and KronRLS
Given a set of drugs D = {d1, . . . , dnd }, targets T ={t1, . . . , tnt }, and the set of training inputs xi (drug-target
pairs) and their binary labels yi ∈ R (where 1 stands for a
known interaction and 0 otherwise), with 1 < i ≤ n, n =
|D||T | (number of drug-target pairs). The RLS approach
minimizes the following function [29]:
J(f ) = 12n
n∑
i=1
(yi − f (xi))2 + λ2 ‖ f ‖
2
K , (1)
where ‖ f ‖K is the norm of the prediction function f on
the Hilbert space associated to the kernel K, and λ > 0
is a regularization parameter which determines the com-
promise between the prediction error and the complexity
of the model. According to the representer theorem [30],
a minimizer of the above objective function admits a dual




aiK(x, xi) , (2)
where K : |D||T | × |D||T | → R is named the pair-
wise kernel function and a is the vector of dual variables
corresponding to each separation constraint. The RLS
algorithm obtains the minimizer of Eq. 1 solving a sys-
tem of linear equations defined by (K + λI)a = y, where
a and y are both n-dimensional vectors consisting of the
parameters ai and labels yi.
One can construct such pairwise kernel as the prod-
uct of two base kernels, namely K((d, t), (d′, t′)) =
KD(d, d′)KT (t, t′), where KD and KT are the base kernels
for drugs and targets, respectively. This is equivalent to
the Kronecker product of the two base kernels [4, 31]:
K = KD ⊗ KT . The size of the kernel matrix makes
the model training computationally unfeasible even for
moderate number of drugs and targets [4].
The KronRLS algorithm is a modification of RLS, and
takes advantage of two specific algebraic properties of the
Kronecker product to speed up model training: the so
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called vec trick [31] and the relation of the eigendecom-
position of the Kronecker product to the eigendecompo-
sition of its factors [11, 32].
Let KD = QDDQTD and KT = QTTQTT be the
eigendecomposition of the kernel matrices KD e KT . The
solution a can be given by solving the following equation
[11]:
a = vec(QTCQTD) , (3)
where vec(·) is the vectorization operator that stacks the
columns of a matrix into a vector, and C is a matrix
defined as:
C = (D ⊗ T + λI)−1vec(QTTYTQD) . (4)
The KronRLS algorithm is well suited for the large pair-
wise space involved on the DTI prediction problem, since
the estimation of vector a using Eqs. 3 and 4 is a much
faster solution compared to the original RLS estimation
process in such scenario. However, it does not support the
use of multiple kernels.
KronRLS MKL
In this work, a vector of different kernels is considered,
i.e., kD = (K1D,K2D, . . . ,KPDD ) and kT = (K1T ,K2T , . . . ,KPTT ),
PD and PT indicate the number of base kernels defined
over the drugs and target set, respectively. In this section,
we propose an extension of KronRLS to handle multiple
kernels.
The kernels can be combined by a linear function, i.e.,
the weighted sum of base kernels, corresponding to the

























correspond to the weights of drug and protein kernels,
respectively.
In [28], the author demonstrated that MKL can be inter-
preted as a particular instance of a kernel machine with
two layers, in which the second layer is a linear function.
His work provides the theoretical basis for the develop-
ment of a MKL extension for the closely related KronRLS
algorithm in our work.
The classification function of Eq. 2 can be written in
matricial form, fa = Ka [29] and applying the well known























)T), where A = unvec(a). Using the same itera-
tive approach considered in previous MKL strategies [13],
we propose the use of a two step optimization process, in
which the optimization of the vector a is interleaved with
the optimization of the kernel weights. Given two initial
weight vectors, β0D and β0T , an optimal value for the vec-
tor a, using Eq. 3 is found, and with such optimal a, we
can proceed to find optimal βD and βT . More specifically,
Eq. 1 can be redefined when a is fixed, and knowing that












T (y − λa). (5)
Since the second term does not depend on K (and thus
does not depend on the kernel weights), and, as y and a
are fixed, it can be discarded from the weights optimiza-
tion procedure. Note that we are not interested in a sparse
selection of base kernels as in [28], therefore we intro-
duce a L2 regularization term to control sparsity [33] of
the kernel weights, also known as a ball constraint. This
term is parameterized by the σ regularization coefficient.
Additionally, we can convert u to its matrix form by the
application of the unvec operator, i.e., U = unvec(u),
and also use a more appropriate matrix norm (Frobenius,
‖ A ‖2≤‖ A ‖F [32]). In this way, for any fixed values of
a and βT , the optimal value for the combination vector is

















while the optimal βT can be found fixing the values of a
















The optimizationmethod used here is the interior-point
optimization algorithm [34] implemented in MATLAB
[35].
Data
The datasets considered were first proposed by [23] and
used by most competing methods [2, 10, 11, 15, 25].
Each dataset consists of a binary matrix, containing the
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known interactions of a determined set of drug targets,
namely Enzyme (E), Ion Channel (IC), GPCR and Nuclear
Receptors (NR), based on information extracted from the
KEGG BRITE [36], BRENDA [37], SuperTarget [38] and
DrugBank databases [39]. All four datasets are extremely
unbalanced, if we consider the whole drug-target inter-
action space, i.e., the number of known interactions is
extremely lower than the number of unknown interac-
tions, as presented in Table 1.
In order to analyze each type of entity from differ-
ent points of view, we extracted 20 (10 for targets and
10 for drugs) distinct kernels from chemical structures,
side-effects, amino acid sequence, biological function, PPI
interactions and network topology (a summary of base
kernels is presented in Table 2).
Protein kernels
Here we use the following information sources about tar-
get proteins: amino acid sequence, functional annotation
and proximity in the protein-protein network. Concern-
ing sequence information, we consider the normalized
score of the Smith-Waterman alignment of the amino acid
sequence (SW) [23], as well as different parametrizations
of theMismatch (MIS) [40] and the Spectrum (SPEC) [41]
kernels. For the Mismatch kernel, we evaluated four com-
binations of distinct values for the k-mers length (k = 3
and k = 4) and the number of maximal mismatches
per k-mer (m = 1 and m = 2), namely MIS-k3m1,
MIS-k3m2, MIS-k4m1 and MIS-k4m2; for the Spec-
trum kernel, we varied the k-mers length (k = 3 and k =
4, SPEC-k3 and SPEC-k4, respectively). Both Mismatch
and Spectrum kernels were calculated using the R package
KeBABS [42].
The Gene Ontology semantic similarity kernel (GO)
was used to encode functional information. GO terms
were extracted from the BioMART database [43], and
the semantic similarity scores between the GO annota-
tion terms were calculated using the csbl.go R package
Table 1 Number drugs, targets and positive instances (known
interactions) vs. the number of negative (or unknown)
interactions on each dataset
Datasets
Nuclear receptors GPCR Ion channel Enzyme
Interactions
Known 90 635 1476 2926
(6.41 %) (3 %) (3.45 %) (1 %)
Unknown 1314 20550 41364 292554
(93.59 %) (97 %) (96.55 %) (99 %)
Entity
Drugs 54 223 210 445
Targets 26 95 204 664




Drugs AERS-bit - AERS bit Side-effects
AERS-freq - AERS freq Side-effects
GIP - Gaussian Interaction Profile Network
LAMBDA - Lambda-k Kernel Chem. Struct.
MARG - Marginalized Kernel Chem. Struct.
MINMAX - MinMax Kernel Chem. Struct.
SIMCOMP - Graph kernel Chem. Struct.
SIDER - Side-effects Similarity Side-effects
SPEC - Spectrum Kernel Chem. Struct.
TAN - Tanimoto Kernel Chem. Struct.
Proteins GIP - Gaussian Interaction Profile Network
GO - Gene Ontology Semantic Similarity Func. Annot.
MIS-k3m1 - Mismatch kernel
(k = 3,m = 1)
Sequences
MIS-k4m1 - Mismatch kernel
(k = 4,m = 1)
Sequences
MIS-k3m2 - Mismatch kernel
(k = 3,m = 2)
Sequences
MIS-k4m2 - Mismatch kernel
(k = 3,m = 2)
Sequences




SPEC-k3 - Spectrum kernel (k = 3) Sequences
SPEC-k4 - Spectrum kernel (k = 4) Sequences
SW - Smith-Waterman aligment score Sequences
[44], with the Resnik algorithm [45]. We also extracted a
similarity measure from the human protein-protein net-
work (PPI), obtained from the BioGRID database [46].
The similarity between each pair of targets was calculated
based on the shortest distance on the corresponding PPI
network, according to:
S(p, p′) = AebD(p,p′),
where A and b parameters were set as in [14] (A =
0.9, b = 1), and D(p, p′) is the shortest hop distance
between proteins p and p′.
Drug kernels
As drug information sources, we consider 6 distinct chem-
ical structure and 3 side-effects kernels. Chemical struc-
ture similarity between drugs was achieved by the applica-
tion of the SIMCOMP algorithm [47] (obtained from [23]),
defined as the ratio of common substructures between
two drugs based on the chemical graph alignment. We
also computed the Lambda-k kernel (LAMBDA) [48], the
Marginalized kernel [49] (MARG), the MINMAX kernel [50],
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the Spectrum kernel [48] (SPEC) and the Tanimoto kernel
[50] (TAN). These later kernels were calculated with the R
Package Rchemcpp [48] with default parameters.
Two distinct side-effects data sources were also consid-
ered. The FDA adverse event reporting system (AERS),
fromwhich side effect keywords (adverse event keywords)
similarities for drugs were first retrieved by [51]. The
authors introduced two types of pharmacological profiles
for drugs, one based on the frequency information of side
effect keywords in adverse event reports (AERS-freq)
and another based on the binary information (presence
or absence) of a particular side-effect in adverse event
reports (AERS-bit). Since not every drug in the Nuclear
Receptors, Ion Channel, GPCR and Enzyme datasets is
also present on AERS-based data, we extracted the simi-
larities of the drugs in AERS, and assigned zero similarity
to drugs not present.
The second side-effect resource was the SIDER
database1 [52]. This database contains information about
commercial drugs and their recorded side effects or
adverse drug reactions. Each drug is represented by a
binary profile, in which the presence or absence of each
side effect keyword is coded 1 or 0, respectively. Both
AERS and SIDER based profile similarities were obtained
by the weighted cosine correlation coefficient between
each pair of drug profiles [51].
Network topology information
We also use drug-target network structure in the form of
a network interaction profile as a similarity measure for
both proteins and drugs. The idea is to encode the con-
nectivity behavior of each node in the subjacent network.
The Gaussian Interaction Profile kernel (GIP) [10] was
calculated for both drugs and targets.
Competing methods
We compare the predictive performance of the KronRLS-
MKL algorithm against other MKL approaches, as well as
in a single kernel context (one kernel for drugs, and one for
targets). In the latter, we evaluate the performance of each
possible combination of base kernels (Table 2) with the
KronRLS algorithm, recently reported as the best method
for predicting drug-target pairs with single paired kernels
[2]. This resulted in a total of 10 × 10 = 100 different
combinations. The best performing pairs were then used
as baselines in our method evaluation, selected according
to two distinct criteria: the kernel pair that achieved the
largest area under the precision recall curve (AUPR) on
the training set, and, a more optimistic approach, which
considered the largest AUPR on the testing set.
Besides the combination of single kernels for drugs and
targets, two different kinds of methods were adopted to
integrate multiple kernels: (1) standard non-MKL ker-
nel methods for DTI prediction, trained on the average
of multiple kernels (respectively for drugs and targets);
(2) actual MKL methods specifically proposed for DTI
prediction.
Non-MKL approaches
We extend state-of-the-art methods [8, 10, 25–27] for the
DTI prediction problem for a multiple kernel context. For
this, initially we average multiple kernels to produce a sin-
gle kernel (respectively for drugs and targets). Once we
have a single average kernel (one for drug and one for
target), we adopt a standard kernel method for DTI pre-
diction, i.e., the base learner. In our experiments, two dis-
tinct previous combinations strategies are used: the mean
of base kernels and the kernel alignment (KA) heuristic,
previously proposed by [53]. We will briefly describe the
base learners, followed by a short overview of the two
combination strategies considered.
The Bipartite Local Model (BLM) [26] is a machine
learning based algorithm, where drug-target pairs are pre-
dicted by the construction of the so called ‘local models’,
i.e., a SVM classifier is trained for each drug in the training
set, and the same is done for targets. Then, the maxi-
mum scores for drugs and targets are used to predict new
drug-target interactions. Since BLM demonstrated supe-
rior performance than Kernel Regression Method (KRM)
[23] in previous studies [2, 26], we did not consider KRM
in our experiments.
The Network-based Random Walk with Restart on the
Heterogeneous network (NRWRH) [8] algorithm predicts
new interactions between drugs and targets by the simu-
lation of a random walk in the network of known drug-
target predictions as well as in the drug-drug and protein-
protein similarity networks. LapRLS and NetLapRLS are
both proposed in [25]. Both are based on the RLS learn-
ing algorithm, and perform similarity normalization by
the application of the Laplacian operator. Predictions are
done for drugs and targets separately, and the final predic-
tion scores are obtained by averaging the prediction result
from drug and target spaces.
As said previously, most previous SVM-based methods
found on the literature can be reduced to the Pairwise Ker-
nel Method (PKM) [27], with the distinction being made
by the kernels used and the adopted combination strat-
egy. PKM starts with the construction of a pairwise kernel,
computed from the drug and target similarities. Given two
drug-target pairs, (d, p) and (d′, p′), and the respective
drug and target similarities, KD and KP, the pairwise ker-
nel is given by K((d, p), (d′, p′) = KD(d, d′) × KP(p, p′).
Once the pairwise matrix is computed, it is then used to
train a SVM classifier.
The PKM [27], KronRLS, BLM, NRWRH, LapRLS and
NetLapRLS algorithms cannot cope withmultiple kernels.
For this reason, we consider two simple methods avail-
able for kernel combination: the mean of base kernels and
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the kernel alignment (KA) heuristic [53]. The mean drug
kernel is computed as K∗D = 1/PD
∑PD
i=1 KiD, and the same
can be done for targets, analogously. KA is a heuristic for
the estimation of kernel weights based on the notion of
kernel alignment [54].More specifically, the weight vector,












where yyT stands for the ideal kernel and y being the label
vector. The alignment A
(
K , yyT) of a given kernel K and
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n
√〈K ,K〉F , (11)
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(yyT)ij. Once such com-
binations are performed, the resulting drug and protein
kernels are then used as input to the learning algorithm.
We refer to the mean and KA heuristics appending the
-MEAN and -KA, respectively, to each base learner.
Multiple kernel approaches
Similarity-based Inference of drug-TARgets (SITAR) [14]
constructs a feature vector with the similarity values,
where each feature is based on one drug-drug and one
gene-gene similarity measure, resulting in a total of PD ×
PT features. Each one is calculated by combining the drug-
drug similarities between the query drug and other drugs
and the gene-gene similarities between the query gene and
other target genes across all true drug-target associations.
The method also performs a feature selection procedure
and yields the final classification scores using a logistic
regression classifier.
Gönen and Kaski [22] proposed the Kernelized Bayesian
Matrix Factorization with Twin Multiple Kernel Learn-
ing (KBMF2MKL) algorithm, extending a previous work
[55] to handle multiple kernels. The KBMF2MKL factor-
izes the drug-target interaction matrix by projecting the
drugs and the targets into a common subspace, where the
projected drug and target kernels aremultiplied. Normally
distributed Kernel weights for each subspace projected
kernel are then estimated without any constraints. The
product of the final combined matrices is then used to
make predictions.
Wang et al. [15] proposes to use a simple heuristic to
previously combine the drug and target similarities, and
then use a SVM classifier to perform the predictions.
Only the maximum similarity values of drug and target
kernel matrices are selected, resulting in two distinct ker-
nels. They are then used to construct a pairwise kernel,
computed from the drug and target similarities. Once the
pairwisematrix is computed, it is then used to train a SVM
classifier. This procedure is also known as the Pairwise
Kernel Method (PKM) [27]. For this reason, we refer to the
approach proposed by [15] by PKM-MAX.
The authors in [15] suggest as further work a weighted
sum approach. They suggest to learn the optimal convex
combination of data sources maximizing the correlation
of the obtained kernel matrix with the topology of drug-
protein network. This objective can be achieved by solving




where K∗D correspond to the optimal combination of drug
kernel matrices with weight vector βD, dist is the drug-
drug distance matrix in the DTI network, and corr rep-
resents the correlation coefficient. Analogously, the same
can be done for targets. We call this method WANG-MKL.
Experimental setup
Previous work [2, 11, 24] suggest that, in the context of
paired input problems, one should consider separately
the experiments where the training and test sets share
common drugs or proteins. In order to achieve a clear
notion of the performance of each method, all competing
approaches were evaluated under 5 runs of three distinct
5-fold cross-validation (CV) procedures:
1. ‘new drug’ scenario: it simulates the task of
predicting targets for new drugs. In this scenario, the
drugs in a dataset were divided in 5 disjoint subsets
(folds). Then the pairs associated to 4 folds of drugs
were used to train the classifier and the remaining
pairs are used to test;
2. ‘new target’ scenario: it corresponds in turn to
predicting interacting drugs for new targets. This is
analogous to the above scenario, however
considering 5 folds of targets;
3. pair prediction: is consists of predicting unknown
interactions between known drugs and targets. All
drug-target interactionswere split in five folds, from
which 4 were used for training and 1 for testing.
Some of the competing methods (PKM-based,
WANG-MKL and SITAR) were trained with
sub-sampled datasets, i.e., we randomly selected the
same number of known interactions among the
unknown interaction set, since these methods cannot
be executed in large networks [2, 4, 14, 15]. Although
balanced classes are unlikely in real scenarios, we also
performed experiments in context (3), using a
sub-sampled test set, obtained by sampling as many
negative examples as positive examples [14, 15] from
the test fold. This experiment is relevant for
comparison to previous work, since most previous
studies on drug-target prediction performed
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under-sampling to evaluate predictive performance
(see Additional file 1: Table S1).2
The hyperparameters of each competing methods were
optimized under a nested CV procedure, using the fol-
lowing values: for the SVM-based methods (PKM, BLM
and WANG-MKL), the SVM cost parameter was evaluated
under the interval {2−1, . . . , 23}; for the KronRLS-based
methods, the λ parameter was evaluated in the inter-
val {2−15, 2−10, . . . , 230}. The σ regularization coefficient
of the KRONRLS-MKL algorithm was also optimized in
the interval {0, 0.25, 0.5, 0.75, 1}. The number of com-
ponents in KBMF2MKL was varied in the interval R ∈
{5, 10, . . . , 40}, and for the LapRLS and NetLapRLS
we varied βd,βt ∈ {0.25, 0.50, . . . , 1}. In NetLapRLS
we also considered two distinct values for γd2, γt2 ∈
{0.01, 0.1}. For NRWRH the restart probability was eval-
uated in the set {0.1, 0.2, . . . , 0.9}. After the hyperpa-
rameters were selected for each method, the outer
loop evaluated the predictive performance for the test
set partition with the model built using the selected
hyperparameters.
Fig. 2 Average performance of each single kernel with the KronRLS algorithm as base learner. The boxplots shows the AUPR performance of drug
and protein kernels across different kernel combinations
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Table 3 Results on MKL Experiments on 5 × 5 cross-validation experiments
Dataset Combination Pairs Targets Drugs
NR [SPEC-k4]-[AERS-freq] † 0.4630 (±0.0215) 0.3851 (±0.0254) 0.2341 (±0.0054)
[SPEC-k4]-[GIP] ∗ 0.5187 (±0.0255) 0.3725 (±0.0247) 0.0949 (±0.0068)
BLM-KA 0.0709 (±0.0048) 0.3441 (±0.0264) 0.3130 (±0.0224)
BLM-MEAN 0.0685 (±0.0062) 0.3453 (±0.0264) 0.2934 (±0.0154)
KBMF2MKL 0.2041 (±0.0150) 0.2059 (±0.0388) 0.1459 (±0.0272)
KRONRLS-KA 0.4321 (±0.0147) 0.3489 (±0.0337) 0.2850 (±0.0126)
KRONRLS-MEAN 0.4078 (±0.0211) 0.3482 (±0.0341) 0.2665 (±0.0109)
KRONRLS-MKL 0.5368 (±0.0137) 0.3541 (±0.0321) 0.3383 (±0.0224)
LAPRLS-KA 0.1989 (±0.0207) 0.2120 (±0.0277) 0.1841 (±0.0044)
LAPRLS-MEAN 0.1870 (±0.0196) 0.2008 (±0.0251) 0.1832 (±0.0022)
NETLAPRLS-KA 0.2310 (±0.0277) 0.2091 (±0.0288) 0.1841 (±0.0044)
NETLAPRLS-MEAN 0.2195 (±0.0273) 0.1989 (±0.0263) 0.1831 (±0.0023)
NRWRH-KA – – 0.1776 (±0.0380) 0.1911 (±0.0116)
NRWRH-MEAN – – 0.1755 (±0.0364) 0.1881 (±0.0109)
PKM-KA 0.1830 (±0.0114) 0.2363 (±0.0387) 0.1741 (±0.0158)
PKM-MAX 0.0946 (±0.0188) 0.0774 (±0.0108) 0.1174 (±0.0080)
PKM-MEAN 0.1702 (±0.0099) 0.2163 (±0.0400) 0.1672 (±0.0152)
SITAR 0.4477 (±0.0658) 0.1396 (±0.0505) 0.0694 (±0.0189)
WANG-MKL 0.3293 (±0.0175) 0.2238 (±0.0300) 0.2628 (±0.0225)
GPCR [SPEC-k4]-[MINMAX] † 0.3246 (±0.0093) 0.5053 (±0.0322) 0.0924 (±0.0055)
[SW]-[GIP] ∗ 0.6188 (±0.0075) 0.4561 (±0.0201) 0.0419 (±0.0014)
BLM-KA 0.0633 (±0.0071) 0.5508 (±0.0123) 0.3000 (±0.0198)
BLM-MEAN 0.0519 (±0.0032) 0.5353 (±0.0135) 0.2526 (±0.0188)
KBMF2MKL 0.4960 (±0.0124) 0.0963 (±0.0346) 0.1408 (±0.0120)
KRONRLS-KA 0.6208 (±0.0081) 0.4727 (±0.0101) 0.3005 (±0.0148)
KRONRLS-MEAN 0.6213 (±0.0085) 0.4461 (±0.0086) 0.2731 (±0.0155)
KRONRLS-MKL 0.6440 (±0.0052) 0.4127 (±0.0126) 0.3161 (±0.0112)
LAPRLS-KA 0.2183 (±0.0067) 0.1458 (±0.0050) 0.1210 (±0.0058)
LAPRLS-MEAN 0.2169 (±0.0066) 0.1369 (±0.0049) 0.1215 (±0.0061)
NETLAPRLS-KA 0.3763 (±0.0096) 0.1451 (±0.0041) 0.1211 (±0.0062)
NETLAPRLS-MEAN 0.3841 (±0.0088) 0.1357 (±0.0039) 0.1221 (±0.0061)
NRWRH-KA – – 0.0762 (±0.0041) 0.1201 (±0.0088)
NRWRH-MEAN – – 0.0704 (±0.0036) 0.1176 (±0.0099)
PKM-KA 0.2625 (±0.0133) 0.2327 (±0.0175) 0.1424 (±0.0146)
PKM-MAX 0.1230 (±0.0106) 0.0652 (±0.0071) 0.0935 (±0.0044)
PKM-MEAN 0.2613 (±0.0178) 0.1632 (±0.0186) 0.1254 (±0.0107)
SITAR 0.5324 (±0.0267) 0.1151 (±0.0538) 0.0283 (±0.0110)
WANG-MKL 0.4240 (±0.0071) 0.3521 (±0.0111) 0.2686 (±0.0274)
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Table 3 Results on MKL Experiments on 5 × 5 cross-validation experiments (Continued)
IC [PPI]-[GIP] † 0.6789 (±0.0078) 0.1548 (±0.0020) 0.0467 (±0.0009)
[SW]-[GIP] ∗ 0.8679 (±0.0056) 0.7301 (±0.0140) 0.0476 (±0.0008)
BLM-KA 0.1169 (±0.0127) 0.7944 (±0.0047) 0.2516 (±0.0304)
BLM-MEAN 0.1106 (±0.0088) 0.7798 (±0.0040) 0.2152 (±0.0257)
KBMF2MKL 0.7671 (±0.0033) 0.4420 (±0.0141) 0.0856 (±0.0044)
KRONRLS-KA 0.8553 (±0.0017) 0.7246 (±0.0071) 0.2039 (±0.0190)
KRONRLS-MEAN 0.8693 (±0.0011) 0.6885 (±0.0067) 0.1887 (±0.0186)
KRONRLS-MKL 0.8769 (±0.0011) 0.6894 (±0.0056) 0.2406 (±0.0259)
LAPRLS-KA 0.3088 (±0.0021) 0.2747 (±0.0031) 0.0942 (±0.0022)
LAPRLS-MEAN 0.3187 (±0.0024) 0.2760 (±0.0032) 0.0939 (±0.0021)
NETLAPRLS-KA 0.5359 (±0.0065) 0.2750 (±0.0032) 0.0931 (±0.0022)
NETLAPRLS-MEAN 0.5560 (±0.0073) 0.2766 (±0.0034) 0.0928 (±0.0023)
NRWRH-KA – – 0.2371 (±0.0046) 0.0720 (±0.0026)
NRWRH-MEAN – – 0.2363 (±0.0042) 0.0712 (±0.0024)
PKM-KA 0.5133 (±0.0235) 0.4151 (±0.0092) 0.1156 (±0.0041)
PKM-MAX 0.1608 (±0.0132) 0.1673 (±0.0038) 0.0660 (±0.0031)
PKM-MEAN 0.5474 (±0.0261) 0.3840 (±0.0062) 0.0998 (±0.0019)
SITAR 0.7505 (±0.0153) 0.1717 (±0.0633) 0.0174 (±0.0046)
WANG-MKL 0.7116 (±0.0214) 0.6009 (±0.0158) 0.2217 (±0.0124)
E [GO]-[GIP] † 0.6900 (±0.0032) 0.2371 (± 0.0025) 0.0124 (±0.0004)
[SW]-[GIP] ∗ 0.8429 (±0.00540) 0.7438 (± 0.0189) 0.0159 (±0.0003)
BLM-KA 0.0471 (±0.0045) 0.8201 (±0.0070) 0.2506 (±0.0060)
BLM-MEAN 0.0374 (±0.0032) 0.8099 (±0.0063) 0.2079 (±0.0051)
KBMF2MKL 0.6722 (±0.0051) 0.0757 (±0.0049) 0.0213 (±0.0004)
KRONRLS-KA 0.8630 (±0.0127) 0.7274 (±0.0071) 0.1829 (±0.0034)
KRONRLS-MEAN 0.8667 (±0.0098) 0.6917 (±0.0062) 0.1655 (±0.0030)
KRONRLS-MKL 0.8818 (±0.0128) 0.7384 (±0.0063) 0.2168 (±0.0050)
LAPRLS-KA 0.1920 (±0.0014) 0.1677 (±0.0072) 0.0682 (±0.0012)
LAPRLS-MEAN 0.1750 (±0.0015) 0.1402 (±0.0055) 0.0646 (±0.0013)
NETLAPRLS-KA 0.2853 (±0.0024) 0.1669 (±0.0042) 0.0670 (±0.0018)
NETLAPRLS-MEAN 0.2548 (±0.0019) 0.1402 (±0.0046) 0.0636 (±0.0016)
NRWRH-KA – – 0.0886 (±0.0011) 0.0403 (±0.0024)
NRWRH-MEAN – – 0.0816 (±0.0006) 0.0383 (±0.0018)
PKM-KA 0.2383 (±0.0069) 0.1905 (±0.0047) 0.0480 (±0.0037)
PKM-MAX 0.0762 (±0.0011) 0.0597 (±0.0007) 0.0323 (±0.0007)
PKM-MEAN 0.2161 (±0.0072) 0.1239 (±0.0032) 0.0382 (±0.0031)
SITAR 0.7558 (±0.0160) 0.0232 (±0.0151) 0.0097 (±0.0111)
WANG-MKL 0.7286 (±0.0046) 0.6663 (±0.0069) 0.1648 (±0.0042)





The evaluation metric considered was the AUPR, as it
allows a good quantitative estimate of the ability to sep-
arate the positive interactions from the negative ones.
According to [56], this metric provides a better qual-
ity estimate for highly unbalanced data, since it punishes
more heavily the existence of false positives (FP). This
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is specially true for the datasets considered, as demon-




As a base study, we evaluate the performance of KronRLS
on all pairs of kernels (10×10 pairs). The AUPR results of
all pairs of kernels for the Nuclear Receptors, GPCR, Ion
Channel and Enzyme datasets are show in more detail in
the supplementary material (see Additional file 1).
The performance of KronRLS varies drastically with
the kernel choice, as clearly demonstrated by the average
performance of each kernel on the single kernel experi-
ments (Fig. 2). For Nuclear Receptors, the best kernel pair
combination was SPEC-k4 and GIP, while GIP and SW
performed best in all other data sets. It is also important
to notice the impact of different parametrizations of the
Mismatch sequence kernel. Its performance decreases as
moremismatches are allowed inside a k-mer. Overall, both
versions of AERS, SIMCOMP, GIP, MINIMAX and SIDER
drug kernels showed better performance, while LAMBDA,
MARG, SPEC and TAN performed worse. For targets, GIP,
GO, MIS-k4m1, SPEC and SW kernels performed better
than other target kernels.
Comparative analysis
In this section, we compare the competing methods in
terms of AUPR for all datasets. Concerning KronRLS,
we will use the best kernel pair (Best Pair) with largest
AUPR as described in the previous section. This will serve
as a baseline to evaluate the MKL approaches. Results
are presented in Table 3. In the pair prediction scenario,
KRONRLS-MKL obtained highest AUPR in all datasets. Its
results are even superior than the performance in compar-
ison to the best kernel pair under the optimistic selection.
The results of KRONRLS-MKL in pair prediction are statis-
tically significant against all other methods (at α = 0.05),
except from KRONRLS-KA and KRONRLS-MEAN, accord-
ing to theWilcoxon rank sum test (Additional file 2). Con-
cerning the subsampled pair prediction, KRONRLS-MKL
achieved highest AUPR in the NR and IC data sets,
and SITAR performed best in the GPCR and Enzyme
data. There it performed second, just after SITAR (see
Additional file 3: Table S1). The highest AUPR values
obtained in the subsampled data sets in comparison to
the unbalanced data sets clearly indicate that performing
predictions in the complete data is a more difficult task.
Moreover, the number of positive examples was negatively
correlated to the dataset size for the complete datasets.
In the ’new target’ scenario, BLM-KA performed best
in 3 of 4 datasets, followed closely by BLM-mean and
KRONRLS-MKL, demonstrating that the local SVMmodel
is more effective in such scenario. BLM-KA performed
better than all evaluated methods with the exception of
BLM-Mean, KBMF-MKL, KRONRLS-KA, KRONRL-MEAN
and KRONRLS-MKL (α = 0.05 Additional file 2). In
the ’new drug’ problem, KRONRLS-MKL obtained higher
AUPR in the NR and GPCR datasets, while BLM-KA had
higher AUPR values in the IC and Enzyme data. Both
KRONRLS-MKL and BLM-KA had statistically significant
higher AUPR (at α = 0.05; Additional file 2) than all other
competing methods. In order to give an overview of the
performance of the evaluated methods, an average rank-
ing of the AUPR values obtained by all methods across the
four datasets is presented in Table 4.
Methods also displayed distinct computational require-
ments. Memory usage was stable accross all methods,
except from the SVM-based algorithms, which demon-
strated quadratic growth of the memory used in relation
to the size of the dataset (BLM, PKM, WANG-MKL). This
is in part due to the construction of the explicit pairwise
kernel (see Additional file 3: Table S3). This fact turns such
methods inadequate for contexts in which subsampling of
pairs is undesirable.
We now discuss about computational time in the pair
prediction scenario. The precomputed kernels approaches
(MEAN and KA) were overall the fastest on average,
with PKM-based methods requiring less time to train and
Table 4 Average ranking over all four datasets
Prediction task
Method Pair Targets Drugs
SINGLE† 7.0 7.8 15.0
SINGLE∗ 3.3 3.3 17.5
BLM-KA 16.0 2.5 1.8
BLM-MEAN 17.0 3.0 4.0
KBMF2MKL 7.3 13.5 13.3
KRONRLS-KA 3.8 4.3 3.8
KRONRLS-MEAN 3.0 5.8 5.0
KRONRLS-MKL 1.0 4.8 1.5
LAPRLS-KA 12.8 11.5 9.8
LAPRLS-MEAN 13.3 12.8 10.5
NETLAPRLS-KA 9.3 12.0 10.3
NETLAPRLS-MEAN 9.0 13.0 11.3
NRWRH-KA – 15.8 12.0
NRWRH-MEAN – 16.8 13.0
PKM-KA 11.8 8.8 9.8
PKM-MAX 15.0 18.5 16.0
PKM-MEAN 12.0 11.0 11.5
SITAR 5.0 17.3 19.0
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test the models (∼1 min), followed by KronRLS-based
and LapRLS-based algorithms(∼20 and 27 min, respec-
tively). KBMF2MKL and BLMwere the slowest, requiring
more than 100 min on average at the same task. The
lower computation time of the heuristic-based methods is
explained by the absence of complex optimization proce-
dures to find the kernel weights. KronRLS-MKL took a lit-
tle less time than KBMF2MKL, taking an average over the
four datasets of 74 min. (see Additional file 3: Table S4).
Predictions on new drug-target interactions
In order to evaluate the quality of final predictions in
a more realistic scenario, we performed an experiment
similar to that described by [10, 26]. We estimate the
most highly ranked drug–target pairs as most likely true
interactions, and performed a search on the current
release of four major databases (DrugBank [39], MATA-
DOR [38], KEGG [57]) and ChEMBL [58]. As the training
datasets were generated almost eight years ago, new
interactions included in these databases will serve as a
external validation set. We exclude interactions already
present in the training data.
We trained all methods with all interactions present
in the original datasets. In the specific case of BLM
and NRWRH, one model for drugs and another for tar-
gets was trained, and then the maximum score for each
DT pair was considered for prediction. Then, we cal-
culated the AUPR for each dataset separately, discard-
ing already known interactions (see Additional file 3:
Table S2). The low AUPR values of all methods indi-
cate the difficulty in performing predictions in such large
search space. An average ranking (Fig. 3) of each method
across all databases indicates that KronRLS methods as
best performing algorithms followed by single kernel
approaches. It is also important to highlight the poor
performance of BLM-KA and BLM-MEAN in this task.
Fig. 3Mean AUPR ranking of each method when compared to the new interactions found on updated databases. The KronRLS-based methods
achieved superior performance when compared to other integration strategies
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This indicates a poor generalization capacity of the BLM
framework to the drug-target prediction problem (see
Table 3).
Next, a more practical assessment of the predicting
power of KRONRLS-MKL is done, by looking to the top
5 ranked interactions predicted by our method (Table 5).
We observe that the great majority of interactions (14 out
of 20) have been already described in ChEMBL, Drug-
Bank or Matador. We focus our discussion in selected
novel interactions. For example, in the Nuclear Receptor
database, the 5th ranked prediction indicates the asso-
ciation of Tretinoin with the nuclear factor RAR-related
orphan receptor A (RORa). Tretinoin is a drug currently
used to treatment of acnes [59]. Interestingly, its molec-
ular activity is associated with the activation of nuclear
receptors of the closelly related RAR family.
This is also a good example to illustrate the benefits for
incorporation of multiple sources of data. Both RORa and
Tretinoin do not share nodes in the training set. All tar-
gets of Tretinoin have a highGO similarity to RORa (mean
value of 0.8368) despite of theirr low sequence similarity
(SW mean value is 0.1563). In addition, one of the targets
RORa is NR0B1 (nuclear receptor subfamily 0, group B,
member 1). This protein is very close to RORa in the PPI
network (similarity score of 0.90).
Concerning Ion Channel models, prediction ranked 2
and 3 indicate the interaction of Verapamil and Diazox-
ide with ATP-binding cassete sub-family C (ABBCC8).
ABBCC8 is one of the proteins encoding the sulfonylurea
receptor (SUR1) and is associated to calcium regulation
and diabetes type I [60]. Interestingly, there are positive
reports of Diazoxide treatments to prevent diabetes in rats
[61].
Evaluation of kernel weigths
The kernel weights given by KBMF2MKL, KRONRLS-MKL
and WANG-MKL, as well as the KA heuristic, can be
used to analyze the ability of such methods to identify
the most relevant information sources. As there is no
guideline or gold standard for this, we resort to a sim-
ple approach: compare the kernel weights (Fig. 4) with
the average performance of each kernel on the single
Table 5 Top five predicted interactions by KRONRLS-MKL
Drug Target
Nuclear Receptors
D00951 Medroxyprogesterone acetate hsa2099 estrogen receptor 1 (D,C)
D00585 Mifepristone hsa2099 estrogen receptor 1 (C)
D00182 Norethisterone hsa2099 estrogen receptor 1 (C)
D00105 Estradiol hsa5241 progesterone receptor (C)
D00094 Tretinoin hsa6095 RAR-related orphan receptor A
GPCR
D02358 Metoprolol hsa154 adrenoceptor beta 2, surface (D,C)
D00283 Clozapine hsa1814 dopamine receptor D3 (D,C,M)
D00371 Theophylline hsa135 adenosine A2a receptor (K,D,C)
D00371 Theophylline hsa134 adenosine A1 receptor (K,D,C)
D00095 Adrenaline hsa155 adrenoceptor beta 3 (K,D,C)
Ion Channel
D00775 Riluzole hsa2898 glutamate receptor, ionotropic, kainate 2 (M)
D02356 Verapamil hsa6833 ATP-binding cassette, sub-family C (CFTR
D00294 Diazoxide hsa10060 ATP-binding cassette, sub-family C (CFTR
D02356 Verapamil hsa56660 potassium channel, two pore domain subfamily K, member 12
D00524 Carbachol hsa1134 cholinergic receptor, nicotinic, alpha 1 (muscle)
Enzyme
D00542 Halothane hsa1571 cytochrome P450, family 2, subfamily E, polypeptide 1 (D,C,M)
D00437 Nifedipine hsa1559 cytochrome P450, family 2, subfamily C, polypeptide 9 (D,C,M)
D00528 Anhydrous caffeine hsa1549 cytochrome P450, family 2, subfamily A, polypeptide 7 (M)
D03670 Deferoxamine hsa1579 cytochrome P450, family 4, subfamily A, polypeptide 11
D00139 Methoxsalen hsa1543 cytochrome P450, family 1, subfamily A, polypeptide 1 (D,M)
Interactions found in KEGG, DrugBank, ChEMBL and Matador are marked as K, D, C and M respectively
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Fig. 4 Comparison of the average final weights obtained by the Kernel Alignment (KA) heuristic, KBMF2MKL, KronRLS-MKL and WANG-MKL
algorithms. As one can note, the KA heuristic demonstrated close to mean weights, while KRONRLS-MKL and WANG-MKL effectively discarded
the most irrelevant kernels
kernel experiments (Fig. 2). First, it is noticeable that
the KA weights are very similar to the average selec-
tion (0.10). This indicates that no clear kernel selection
is performed. WANG-MKL and KRONRLS-MKL give low
weights to drug kernels LAMBDA, MARG, MINIMAX, SPEC
and TAN and protein kernel MIS-k3m2. These kernels
have overall worst AUPR in the single kernel experiments,
which indicates an agreement with both selection pro-
cedures. Although the weights assigned by KBMF2MKL
are not subject to convex constraints, as indicated by
the larger weights assigned to all kernels, they also pro-
vide a notion of quality of base kernels. We can observe
a stronger preference to the GIP kernel, in all datasets,
even though the algorithm assigned a high weight
for the lower quality MIS-k3m2 in three of the four
datasets.
Conclusions
We have presented a new Multiple Kernel Learning algo-
rithm for the bipartite link prediction problem, which is
able to identify and select the most relevant information
sources for DTI prediction. Most previous MKL methods
mainly solve the problem of MKL when kernels are built
over the same set of entities, which is not the case for
the bipartite link prediction problem, e.g. drug-target net-
works. Regarding predictions in drug-target networks, the
sampling of negative/unknown examples, as a way to cope
with large data sets, is a clear limitation [2]. Our method
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takes advantage of the KronRLS framework to efficiently
perform link prediction on data with arbitrary size.
In our experiments, the KronRLS-MKL algorithm
demonstrated an interesting balance between accuracy
and computational cost in relation to other approaches.
It performed best in the “pair” prediciton problem and
the “new target” problem. In the ’new drug’ and ’new tar-
get’ prediction tasks, BLM-KA was also top ranked. This
method has a high computational cost. This arises from
the fact it requires a classifier for each DT pair [2]. More-
over, it obtained poor results in the evaluation scenario to
predict novel drug-protein pairs interactions.
The convex constraint estimation of kernel weights cor-
related well with the accuracy of a brute force pair kernel
search. This non-sparse combination of kernels possibly
increased the generalization of the model by reducing the
bias for a specific type of kernel. This usually leads to
better performance, since the model can benefit from dif-
ferent heterogeneous information sources in a systematic
way [33]. Finally, the algorithm performance was not sen-
sitive to class unbalance and can be trained over the whole
interaction space without sacrificing performance.
Endnotes
1http://sideeffects.embl.de/.
2NRWRH cannot be applied to the pair prediction [8],
by which this method was not considered in such context.
Additional files
Additional file 1: Figure. Single kernel experiments on the Nuclear
Receptor dataset with the KronRLS algorithm as base learner. The heatmap
shows the AUPR performance of different kernel combinations; red means
higher AUPR. (PDF 460 kb)
Additional file 2: Spreadsheet. p-values under pairwise Wilcoxon Rank
Sum statistical tests of all competing methods in pair, drug and target
prediction tasks. (XLS 24 kb)
Additional file 3: Supplementary Tables. AUPR Results of competing
methods under pair prediction setting considering subsampled test sets
(S1); AUPR results of predicted scores against new interactions found on
current release of KEGG, Matador, Drugbank and ChEMBL databases (S2);
Average memory (MB) usage during training and testing of competing
methods (S3); Average time (minutes) required to train and test the models
with the competing methods (S4). (PDF 89.7 kb)
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
Conceived and designed the experiments: AN RP IC. Performed the
experiments: AN. Analyzed the data: AN RP IC. All authors read and approved
the final manuscript.
Acknowledgements
The authors thank the authors of the studies by [23] for making their data
publicly available. This work was supported by the Interdisciplinary Center for
Clinical Research (IZKF Aachen), RWTH Aachen University Medical School,
Aachen, Germany; DAAD; and Brazilian research agencies: FACEPE, CAPES and
CNPq.
Author details
1Center of Informatics, UFPE, Recife, Brazil. 2Department of Statistics and
Informatics, UFRPE, Recife, Brazil. 3IZKF Computational Biology Research Group,
Institute for Biomedical Engineering, RWTH Aachen University Medical School,
Aachen, Germany. 4Aachen Institute for Advanced Study in Computational
Engineering Science (AICES), RWTH Aachen University, Aachen, Germany.
Received: 23 July 2015 Accepted: 5 January 2016
References
1. Csermely P, Korcsmáros T, Kiss HJM, London G, Nussinov R. Structure
and dynamics of molecular networks: a novel paradigm of drug
discovery: a comprehensive review. Pharmacol Ther. 2013;138(3):
333–408. doi:10.1016/j.pharmthera.2013.01.016.
2. Ding H, Takigawa I, Mamitsuka H, Zhu S. Similarity-based machine
learning methods for predicting drug-target interactions: a brief review.
Brief Bioinform. 2013. doi:10.1093/bib/bbt056.
3. Chen X, Yan CC, Zhang X, Zhang X, Dai F. Drug – target interaction
prediction : databases , web servers and computational models. Brief
Bioinform. 20151–17. doi:10.1093/bib/bbv066.
4. Yamanishi Y. Chemogenomic approaches to infer drug–target interaction
networks. Data Min Syst Biol. 2013;939:97–113.
doi:10.1007/978-1-62703-107-3.
5. Dudek AZ, Arodz T, Gálvez J. Computational methods in developing
quantitative structure-activity relationships (QSAR): a review. Comb Chem
High Throughput Screen. 2006;9(3):213–8.
6. Sawada R, Kotera M, Yamanishi Y. Benchmarking a wide range of
chemical descriptors for drug-target interaction prediction using a
chemogenomic approach. Mol Inform. 2014;33(11-12):719–31.
doi:10.1002/minf.201400066.
7. Cheng F, Liu C, Jiang J, Lu W, Li W, Liu G, et al. Prediction of drug-target
interactions and drug repositioning via network-based inference. PLoS
Comput Biol. 2012;8(5):1002503. 10.1371/journal.pcbi.1002503.
8. Chen X, Liu MX, Yan GY. Drug-target interaction prediction by random
walk on the heterogeneous network. Mol BioSyst. 2012;8(7):1970–8.
doi:10.1039/c2mb00002d.
9. Yamanishi Y, Kotera M, Kanehisa M, Goto S. Drug-target interaction
prediction from chemical, genomic and pharmacological data in an
integrated framework. Bioinformatics (Oxford, England). 2010;26(12):
246–54. doi:10.1093/bioinformatics/btq176.
10. van Laarhoven T, Nabuurs SB, Marchiori E. Gaussian interaction profile
kernels for predicting drug-target interaction. Bioinformatics (Oxford,
England). 2011;27(21):3036–43. doi:10.1093/bioinformatics/btr500.
11. Pahikkala T, Airola A, Pietila S, Shakyawar S, Szwajda A, Tang J, et al.
Toward more realistic drug-target interaction predictions. Brief Bioinform.
2014. doi:10.1093/bib/bbu010.
12. Pahikkala T, Airola A, Stock M, Baets BD, Waegeman W. Efficient
regularized least-squares algorithms for conditional ranking on relational
data. Mach Learn. 2013;93:321–356. arXiv:1209.4825v2.
13. Gönen M, Alpaydın E. Multiple kernel learning algorithms. J Mach Learn
Res. 2011;12:2211–268.
14. Perlman L, Gottlieb A, Atias N, Ruppin E, Sharan R. Combining drug and
gene similarity measures for drug-target elucidation. J Comput Biol.
2011;18(2):133–45. doi:10.1089/cmb.2010.0213.
15. Wang YC, Zhang CH, Deng NY, Wang Y. Kernel-based data fusion
improves the drug-protein interaction prediction. Comput Biol Chem.
2011;35(6):353–62. doi:10.1016/j.compbiolchem.2011.10.003.
16. Wang Y, Chen S, Deng N, Wang Y. Drug repositioning by kernel-based
integration of molecular structure, molecular activity, and phenotype
data. PLoS ONE. 2013;8(11):78518. doi:10.1371/journal.pone.0078518.
17. Ben-Hur A, Noble WS. Kernel methods for predicting protein-protein
interactions,. Bioinformatics (Oxford, England). 2005;21 Suppl 1:38–46.
doi:10.1093/bioinformatics/bti1016.
18. Hue M, Riffle M, Vert J-p, Noble WS. Large-scale prediction of
protein-protein interactions from structures. BMC Bioinforma.
2010;11:144.
19. Ammad-Ud-Din M, Georgii E, Gönen M, Laitinen T, Kallioniemi O,
Wennerberg K, et al. Integrative and Personalized QSAR Analysis in Cancer
by Kernelized Bayesian Matrix Factorization. J Chem Inf Model. 2014;1:.
doi:10.1021/ci500152b.
Nascimento et al. BMC Bioinformatics  (2016) 17:46 Page 16 of 16
20. Lanckriet GR, Deng M, Cristianini N, Jordan MI, Noble WS. Kernel-based
data fusion and its application to protein function prediction in yeast. In:
Pacific Symposium on Biocomputing. World Scientific; 2004. p. 300–11.
21. Yu G, Zhu H, Domeniconi C, Guo M. Integrating multiple networks for
protein function prediction. BMC Syst Biol. 2015;9(Suppl 1):3.
10.1186/1752-0509-9-S1-S3.
22. Gönen M, Kaski S. Kernelized Bayesian Matrix Factorization. IEEE Trans
Pattern Anal Mach Intell. 2014;36(10):2047–2060.
23. Yamanishi Y, Araki M, Gutteridge A, Honda W, Kanehisa M. Prediction of
drug-target interaction networks from the integration of chemical and
genomic spaces. Bioinformatics (Oxford, England). 2008;24(13):232–40.
doi:10.1093/bioinformatics/btn162.
24. Park Y, Marcotte EM. Flaws in evaluation schemes for pair-input
computational predictions. Nat Methods. 2012;9(12):1134–6.
doi:10.1038/nmeth.2259.
25. Xia Z, Wu LY, Zhou X, Wong STC. Semi-supervised drug-protein
interaction prediction from heterogeneous biological spaces. BMC Syst
Biol. 2010;4 Suppl 2(Suppl 2):6. doi:10.1186/1752-0509-4-S2-S6.
26. Bleakley K, Yamanishi Y. Supervised prediction of drug-target interactions
using bipartite local models. Bioinformatics (Oxford, England).
2009;25(18):2397–403. doi:10.1093/bioinformatics/btp433.
27. Jacob L, Vert JP. Protein-ligand interaction prediction: an improved
chemogenomics approach. Bioinformatics (Oxford, England). 2008;24(19):
2149–56. doi:10.1093/bioinformatics/btn409.
28. Dinuzzo F. Learning functions with kernel methods. 2011. PhD thesis,
University of Pavia.
29. Rifkin R, Yeo G, Poggio T. Regularized least-squares classification. Nato
Science Series Sub Series III Computer and Systems Sciences. 2003;190:
131–54.
30. Kimeldorf G, Wahba G. Some results on Tchebycheffian spline functions.
J Math Anal Appl. 1971;33(1):82–95.
31. Kashima H, Oyama S, Yamanishi Y, Tsuda K. On pairwise kernels: an
efficient alternative and generalization analysis. Adv Data Min Knowl Disc.
2009;5476:1030–7.
32. Laub AJ. Matrix Analysis for Scientists and Engineers. Davis, California:
SIAM; 2005, pp. 139–44.
33. Kloft M, Brefeld U, Laskov P, Sonnenburg S. Non-sparse multiple kernel
learning. In: NIPS Workshop on Kernel Learning: Automatic Selection of
Optimal Kernels (Vol. 4); 2008.
34. Byrd RH, Hribar ME, Nocedal J. An interior point algorithm for large-scale
nonlinear programming. SIAM J Optim. 1999;9(4):877–900.
doi:10.1137/S1052623497325107.
35. MATLAB. version 8.1.0 (R2013a). Natick, Massachusetts: The MathWorks
Inc.; 2013.
36. Kanehisa M, Araki M, Goto S, Hattori M, Hirakawa M, Itoh M, et al. KEGG
for linking genomes to life and the environment. Nucleic Acids Res.
2008;36(suppl 1):480–4.
37. Schomburg I, Chang A, Ebeling C, Gremse M, Heldt C, Huhn G, et al.
BRENDA, the enzyme database: updates and major new developments.
Nucleic Acids Res. 2004;32(suppl 1):431–3.
38. Günther S, Kuhn M, Dunkel M, Campillos M, Senger C, Petsalaki E, et al.
SuperTarget and Matador: resources for exploring drug-target
relationships. Nucleic Acids Res. 2008;36(suppl 1):919–22.
39. Wishart DS, Knox C, Guo AC, Cheng D, Shrivastava S, Tzur D, et al.
DrugBank: a knowledgebase for drugs, drug actions and drug targets.
Nucleic Acids Res. 2008;36(suppl 1):901–6.
40. Eskin E, Weston J, Noble WS, Leslie CS. Mismatch String Kernels for SVM
Protein Classification. In: Advances in neural information processing
systems-NIPS; 2002. p. 1417–1424.
41. Leslie CS, Eskin E, Noble WS. The spectrum kernel: a string kernel for SVM
protein classification. In: Pac Symp Biocomput vol. 7; 2002. p. 566–575.
42. Palme J, Hochreiter S, Bodenhofer U. KeBABS - an R package for kernel-
based analysis of biological sequences. Bioinformatics. 2015;31(15):
2574–2576. doi:10.1093/bioinformatics/btv176.
43. Smedley D, Haider S, Durinck S, Al E. The BioMart community portal: an
innovative alternative to large, centralized data repositories. Nucleic Acids
Res. 2015. doi:10.1093/nar/gkv350.
44. Ovaska K, Laakso M, Hautaniemi S. Fast Gene Ontology based clustering
for microarray experiments. BioData Min. 2008;1(1):11.
45. Resnik P. Semantic Similarity in a Taxonomy: An Information Based
Measure and Its Application to Problems of Ambiguity in Natural
Language. J Artif Intell Res. 1999;11:95–130.
46. Stark C, Breitkreutz BJ, Reguly T, Boucher L, Breitkreutz A, Tyers M.
BioGRID: a general repository for interaction datasets. Nucleic Acids Res.
2006;34(suppl 1):535–9.
47. Hattori M, Okuno Y, Goto S, Kanehisa M. Development of a chemical
structure comparison method for integrated analysis of chemical and
genomic information in the metabolic pathways. J Am Ceram Soc.
2003;125(39):11853–65.
48. Klambauer G, Wischenbart M, Mahr M, Unterthiner T, Mayr A,
Hochreiter S. Rchemcpp: a web service for structural analoging in
ChEMBL, Drugbank and the Connectivity Map. Bioinformatics.
2015. Advance access doi:10.1093/bioinformatics/btv373.
49. Kashima H, Tsuda K, Inokuchi A. Marginalized kernels between labeled
graphs. In: ICML, vol. 3; 2003. p. 321–328.
50. Ralaivola L, Swamidass SJ, Saigo H, Baldi P. Graph kernels for chemical
informatics. Neural Netw. 2005;18(8):1093–110.
doi:10.1016/j.neunet.2005.07.009.
51. Takarabe M, Kotera M, Nishimura Y, Goto S, Yamanishi Y. Drug target
prediction using adverse event report systems: A pharmacogenomic
approach. Bioinformatics. 2012;28(18):611–8.
doi:10.1093/bioinformatics/bts413.
52. Kuhn M, Campillos M, Letunic I, Jensen LJ, Bork P. A side effect resource
to capture phenotypic effects of drugs. Mol Syst Biol. 2010;6(1):343.
53. Qiu S, Lane T. A framework for multiple kernel support vector regression
and its applications to siRNA efficacy prediction. IEEE/ACM Trans Comput
Biol Bioinf. 2009;6(2):190–9.
54. Cristianini N, Kandola J, Elisseeff A, Shawe-Taylor J. On kernel-target
alignment. In: Advances in Neural Information Processing Systems 14.
Cambridge MA: MIT Press; 2002. p. 367–73.
55. Gönen M. Predicting drug-target interactions from chemical and genomic
kernels using Bayesian matrix factorization. Bioinformatics (Oxford,
England). 2012;28(18):2304–10. doi:10.1093/bioinformatics/bts360.
56. Davis J, Goadrich M. The relationship between Precision-Recall and ROC
curves. In: Proceedings of the 23rd international conference on Machine
learning - ICML ’06. New York, NY, USA: ACM; 2006. p. 233–40.
doi:10.1145/1143844.1143874.
57. Kanehisa M, Goto S. KEGG: kyoto encyclopedia of genes and genomes.
Nucleic Acids Res. 2000;28(1):27–30.
58. Bento AP, Gaulton A, Hersey A, Bellis LJ, Chambers J, Davies M, et al.
The ChEMBL bioactivity database: an update. Nucleic Acids Res.
2014;42(D1):1083–90. doi:10.1093/nar/gkt1031.
59. Webster GF. Topical tretinoin in acne therapy. J Am Acad Dermatol.
1998;39(2):38–44.
60. REIS A, VELHO G. Sulfonylurea receptor-1 (sur1): Genetic and metabolic
evidences for a role in the susceptibility to type 2 diabetes mellitus.
Diabetes Metab. 2002;28(1):14–19.
61. Huang Q, Bu S, Yu Y, Guo Z, Ghatnekar G, Bu M, et al. Diazoxide
prevents diabetes through inhibiting pancreatic β-cells from apoptosis
via bcl-2/bax rate and p38-β mitogen-activated protein kinase.
Endocrinology. 2007;148(1):81–91.
